ABSTRACT
Radiotherapy is one of the latest of a long line of potential antiproliferative agents to be enthusiastically tested as an adjunct to angioplasty. In over 100 years of clinical experience, radiotherapy has proven highly effective in inhibiting cellular proliferation, both in malignant and benign disease. Examples of benign hyperplastic entities effectively treated with radiotherapy include the exuberant fibroblastic activity of keloid scar formation, heterotopic ossification, desmoid/aggressive fibromatosis, Peyronie’s disease, and pterygium.1-5 In these benign proliferative disorders, doses of 700-1000 cGy in one treatment or fractionated treatments after the stimuli have proven effective in inhibiting fibroblastic activity without significantly interfering with the normal healing process.
